UBXN11 (UBX domain protein 11) is a cytosolic protein containing ubiquitin-binding domains that participates in proteasome-mediated protein degradation and may regulate actin cytoskeleton reorganization 1. While its precise molecular mechanism remains incompletely characterized, emerging evidence indicates UBXN11 plays a significant role in cancer pathogenesis. In colorectal cancer, UBXN11 overexpression promotes tumorigenesis through NF-κB signaling pathway activation and correlates with reduced overall survival 2. UBXN11 mutations have been identified as recurrent alterations in HPV-associated sinonasal squamous cell carcinoma 34. In lung cancer, a UBXN11 single-nucleotide polymorphism was associated with significantly worse disease-free survival in EGFR-mutant patients receiving erlotinib adjuvant therapy 5, and a 3'UTR variant affecting UBXN11 expression shows cross-ancestry association with lung cancer susceptibility 6. In systemic lupus erythematosus, UBXN11 was identified in disease-associated regulatory networks in multiple immune cell populations, linking it to RND family GTPase signaling and immune dysregulation 1. These findings suggest UBXN11 functions as an oncogenic regulator in multiple cancer types and immune-mediated diseases, making it a potential therapeutic target and prognostic biomarker.